Spelling suggestions: "subject:"imunoterapia""
11 |
Ocenění společnosti Stallergenes SA / The evaluation of Stallergenes SAHorčička, Jan January 2011 (has links)
Master's thesis focuses on evalution of Stallergenes SA. Theoretical part starts with clarifying the background of the company and sector it is situated in. It is followed by outlining the principles and methods of financial analysis. Theoretical part is ended by introduction of the enterprise evaluation methods. Practical part contains strategic analysis -- characteristics of the sector, competition analysis and prediction of future development. Next, the financial analysis is performed. The evaluation is done by using book value method, discounted cash flow method and method based on EVA model.
|
12 |
Interakce povrchového markeru imunitních buněk s nízkomolekulárními ligandy a jejich polymerními konjugáty / Interaction of a surface marker of immune cells with low-molecular weight ligands and their polymer conjugatesŠimonová, Lenka January 2019 (has links)
Millions of people worldwide die of cancer every year. In the last decade, im- munotherapy offered new treatment options achieving long-lasting remissions in a number of patients. Several new immunotherapy-based drugs have been ap- proved by Food and Drug Administration. However, majority of patients either do not respond or soon relapse. Combination of therapies as well as exploring new immune checkpoints seems promising. This thesis focuses on the new immunotherapeutic target CD73. CD73 is membrane ectonucleotidase, widely expressed on the regulatory leukocytes and on cancer cells. The enzymatically active CD73 contributes to the tumour mi- croenvironment by production of immunosuppressive adenosine. This novel im- mune checkpoint is being intensively studied. This thesis aims on development of new approaches for targeting and inhibition of CD73. Soluble recombinant CD73 (rhCD73) was prepared in mammalian expression system and transfectants stably expressing membrane-bound CD73 were prepared as well. Inhibitors necessary for both of my goals have been designed based on published inhibitor of CD73. Development and evaluation of novel antibody mimetic for CD73 characteri- sation was done. The so-called iBody, HPMA polymer conjugate decorated with CD73 inhibitor for targeting, fluorophore for...
|
13 |
Tumor-infiltrující T buňky a jejich role v adoptivní buněčné imunoterapii nádorových onemocnění / Tumor-infiltrating T cells and their role in adoptive cell immunotherapy of cancerStřížová, Zuzana January 2020 (has links)
Cancer immunotherapy has become a leading treatment modality in metastatic diseases. Although this novel therapy has changed the therapeutic algorithms and patients' outcomes in multiple malignancies, certain proportions of patients still fail to respond to these approaches. In our studies, we aimed to address the main mechanisms of tumor resistance to cancer immunotherapy. We have systematically defined the main challenges in adoptive cell transfer. We have focused on two key mechanisms of the tumor resistance to immunotherapy: poor trafficking of adoptively transferred immune cells into tumors, and the death receptor-induced apoptosis of the tumor-infiltrating immune cells. In our work, we have gone beyond the tumor tissue and searched for the immune cell populations and novel targets that would help to challenge the two mechanisms of resistance. Our data uncovered the therapeutic potential of the paratumoral tissue compartments and, thus, provided new avenues on how to challenge solid tumors by immunotherapy.
|
14 |
Příprava chimerických VLP myšího polyomaviru nesoucích epitopy maligního melanomu / Construction of mouse polyomavirus chimeric VLP bearing melanoma epitopesKojzarová, Martina January 2011 (has links)
Major capside protein of Polyomaviridae family viruses is able to selfassemble into virus-like particle (VLP) even without the presence of minor proteins, bind exogenous DNA non-specifically and recognise the receptor on the cellular surface. These characteristics determine its use as vector in gene therapy or immunotherapy. It was discovered before that MPyV VLPs significantly stimulate immune system and have strong adjuvant effect. Chimeric VLP derived from mouse polyomavirus carrying exogenous antigene or epitop is supposed to elicit specifically targeted immune response after immunisation. The main obstacle is choice of immunogene that is strong enough to cause adequate immune response. The goal of this thesis was to construct chimeric particles carrying epitop of malignant melanoma, one of the most immunogenic tumours, on their surface, using methods of genetic engineering. For future research of particle's immunogenic properties three types of particles were developed - particles with human and mouse melanoma epitopes, respectively and control particles with ovalbumine epitop. For the purpose of production of chimeric protein was used baculovirus expression system. It was verified then, with the use of electron microscopy, that introduction of tumour antigen into one of surface loops of VP1...
|
15 |
Interakce povrchového markeru imunitních buněk s nízkomolekulárními ligandy a jejich polymerními konjugáty / Interaction of a surface marker of immune cells with low-molecular weight ligands and their polymer conjugatesŠimonová, Lenka January 2019 (has links)
Millions of people worldwide die of cancer every year. In the last decade, im- munotherapy offered new treatment options achieving long-lasting remissions in a number of patients. Several new immunotherapy-based drugs have been ap- proved by Food and Drug Administration. However, majority of patients either do not respond or soon relapse. Combination of therapies as well as exploring new immune checkpoints seems promising. This thesis focuses on the new immunotherapeutic target CD73. CD73 is membrane ectonucleotidase, widely expressed on the regulatory leukocytes and on cancer cells. The enzymatically active CD73 contributes to the tumour mi- croenvironment by production of immunosuppressive adenosine. This novel im- mune checkpoint is being intensively studied. This thesis aims on development of new approaches for targeting and inhibition of CD73. Soluble recombinant CD73 (rhCD73) was prepared in mammalian expression system and transfectants stably expressing membrane-bound CD73 were prepared as well. Inhibitors necessary for both of my goals have been designed based on published inhibitor of CD73. Development and evaluation of novel antibody mimetic for CD73 characteri- sation was done. The so-called iBody, HPMA polymer conjugate decorated with CD73 inhibitor for targeting, fluorophore for...
|
16 |
Příprava fúzních domén lidských imunoreceptorů pro jejich využití v imunoterapii / Preparation of fusion domains of human immunoreceptors for their utilization in immunotherapyCmunt, Denis January 2019 (has links)
The functions of the immune system include immunosurveillance of transformed cells, i.e., the ability to eliminate these cells before they become harmful to the organism. If the transformed cells succeed to escape the immune system surveillance, an oncological disease develops. The tumour immunotherapy aims to stimulate the immune system mechanisms to fight against the tumour. Lately, there's an interest in using NK cells in the immunotherapy of tumours. These cells appertain to the innate immune system and participate in immunosurveillance. When an NK cell encounters a target cell, its activation depends on the integration of signals from the surface activating and inhibiting receptors which bind ligands on the surface of the target cell. Upon activation, NK cell exhibits a cytotoxic response against the target cell. The use of NK cells in immunotherapy includes, among others, the testing of bispecific fusion proteins which can bind a tumour surface antigen by one part and NK cell activating receptor by the other part. Thus, these fusion proteins mediate a contact between both cells and trigger the cytotoxic response. This work presents a preparation of bispecific fusion proteins which consist of an activating ligand MICA (for the receptor NKG2D) or B7H6 (for the receptor NKp30), and a nanobody...
|
17 |
Histologická analýza terapie melanomu B16-F10 pomocí agonistů TLRs a fagocytárních receptorů / Histologic analysis of melanoma B16-F10 therapy by agonist of TLRs and fagocyte receptorsDIVOKÁ, Petra January 2014 (has links)
The aim of submited Thesis was to contribute to illustration on effect of TLR and fagocytate receptors in melanoma B16-F10 treatment with mouse model. Currently, a consequence of different ligands of fagocyte receptors and their combination with liposacharide (LPS) was tested. Ligands of fagocytate receptors was used in form enabled inside tumor cells anchoring. It deals with these compounds: f-MLFKK-BAM4000, laminarin-BAM4000, mannan-BAM4000. Gained results confirmed that previously observed huge synergy of LPS (activation of TLR4) and activation of phagocytic receptors by ligands anchored to tumor cells found the clarification in the form of extensive necrotization of tumor mass at the histological level.
|
18 |
Vliv nádorového mikroprostředí, buněčné a humorální imunity na patogenezi nádorových onemocnění. / Influence of tumor microenvironment, cellular and humoral immunity on cancer pathogenesis.Špaček, Jan January 2020 (has links)
Cancer is the second leading cause of death in the Czech Republic. Breast cancer and colorectal cancer have relatively high mortality rate. One of the areas of current clinical research in oncology is the study of prognostic biomarkers, which aims to optimize the decision-making process for a patient. Immune response and processes in the tumor microenvironment have been shown to influence to a large extent the biological nature of the tumor in terms of its aggressiveness and ability to metastasize in the host's body. There are certain tumors that could induce a strong immune response, while others do not. The ability to induce an anti-tumor cell response and to attract specific lymphocyte subpopulations directly into tumor tissue has been shown to be very closely related to the prognosis of cancer patients. There is evidence and correlation of the presence of so-called tumor infiltrating lymphocytes in tumor tissue and overall patient survival. Stratification of cancer patients based on immuno-predictors both in the plasma and directly in the tumor microenvironment makes it possible to identify suitable candidates for rediscovered modern anti-tumor immunotherapy, which can already be considered a standard therapeutic modality. In our projects, we focused on the identification of biomarkers that...
|
19 |
Adoptivní transfer tumor-specifických lymfocytů v imunoterapii nádorových onemocnění / Adoptive transfer of tumor-specific lymphocytes for cancer immunotherapyVávrová, Kateřina January 2020 (has links)
Prostate cancer is the second leading cause of cancer death in men in Europe and the US. In the context of previous preclinical experiments and clinical studies there are certain assumptions predicating successful application of immunotherapy in the treatment of patients with prostate cancer. Promising results have been achieved by a combination of different treatment modalities which provide a synergistic antitumor effect. One of these combinatorial options is the use of antitumor vaccines and adoptive T cell transfer. The topic of this thesis is to provide a fresh insight into the past and current trends following the long-term candidate's department program in the field of anti-tumor immunotherapy. The experimental part of this thesis revolves around our own results published in this field. The introductory chapter delivers a basic overview of cellular mechanisms of anti-tumor immunity and the role of individual immune components in these processes. Following chapters are dedicated to current immunotherapeutic approaches with emphasis on the adoptive T cell transfer and implication of this technology in the treatment of prostate cancer. The results section describes the establishment of our protocol for adoptive T cell transfer as well as the protocol for ex vivo enrichment of human T cell...
|
20 |
Optimalizace CAR T lymfocytů pro imunoterapii hematologických malignit / Optimizing chimeric antigenic receptors (CARs) T-cells for immunotherapy of hematological malignanciesMucha, Martin January 2021 (has links)
Immunotherapy based on chimeric antigen receptor (CAR)-expressing T lymphocytes has proven to be highly successful in the treatment of acute lymphoblastic leukemia (ALL), leading to development of CAR-based immunotherapies for other hematologic malignancies. Currently, efforts are underway to refine T cell modifications to make patient treatment more effective. Each time, this modification then needs to be empirically validated in in vitro experiments. We decided to study the effect of the cytokine IL-21 on the antitumor function of CD19-specific CAR T cells using in vitro assays. A construct that co-expressed IL-21 under the control of the inducible NFAT promoter together with CARs against CD19 was introduced into T cells. In a series of experiments, the properties of these cells were compared after coculture with tumor B cell lines and CLL cells obtained from patients. The results showed that CAR T cells that express IL-21 proliferate and activate better, even after repeated stimulation with leukemia cells. In addition to CARs specific against the CD19 molecule, we also investigated CARs specific against the CLL1 molecule, which has been described in the literature as one of the promising targets for the treatment of AML. We prepared CAR T cells against CLL1 producing IL-21. For this purpose, we...
|
Page generated in 0.0427 seconds